How does transfusion-associated graft-versus-host disease compare to hematopoietic cell transplantation-associated graft-versus-host disease?
Acute GVHD
Allogeneic hematopoietic cell transplantation (allo-hct)
Chronic GVHD
Stem cell transplantation-associated graft-versus-host disease (SCT-GVHD)
Transfusion
Transfusion-associated graft-versus-host disease (TA-GVHD)
Journal
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
ISSN: 1473-0502
Titre abrégé: Transfus Apher Sci
Pays: England
ID NLM: 101095653
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
pubmed:
26
2
2022
medline:
25
5
2022
entrez:
25
2
2022
Statut:
ppublish
Résumé
Transfusion-associated graft-versus-host disease (TA-GVHD) is a rare life-threatening complication of blood transfusion caused by donor T cells that escape rejection by the recipient immune system. These donor T cells drive recipient tissue damage in response to host antigens. On the other hand, GVHD occurring after allogeneic hematopoietic cell transplantation (HCT-GVHD) is also caused by donor T cells, but its pathophysiology is more complex and differs due to the effects of tissue damage caused by pre-HCT conditioning and profound immunosuppression. Both TA-GVHD and HCT-GVHD can be fatal; however, mortality is higher with TA-GVHD due to the paucity of treatment options. Here, we compare and summarize the presentation, diagnosis, pathophysiology, prevention, and treatment of TA-GVHD and HCT-GVHD.
Identifiants
pubmed: 35210194
pii: S1473-0502(22)00067-2
doi: 10.1016/j.transci.2022.103405
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
103405Informations de copyright
Copyright © 2022. Published by Elsevier Ltd.